Two randomized, double-blind, placebo-controlled trials published in 2025 reported that daily supplementation with 1,500 mg of curcumin for 12 months significantly reduced liver fat content, liver stiffness, and markers of inflammation in adults with metabolic dysfunction-associated steatotic liver disease. The first trial, published in the International Journal of Molecular Sciences in September 2025, enrolled 227 obese adults with Type 2 diabetes and fatty liver disease. The second trial, published in Nutrients in June 2025 and conducted at Mahidol University in Bangkok, enrolled 78 patients with the same condition. Both studies recorded statistically significant improvements across all primary liver health measurements, according to the study reports.
The findings add to the body of evidence suggesting that curcumin, the active compound in turmeric, may offer a non-pharmaceutical intervention for a condition affecting an estimated 38% of adults worldwide, as noted by the World Health Organization. Researchers emphasized that the results met the gold-standard criteria for clinical research, indicating the spice compound produced measurable beneficial effects in both obese and diabetic populations. The trials used a standardized dose of 1,500 mg of curcumin per day over a 12-month period. [1] [2]
Read Full Article: https://www.naturalnews.com/2026-05-08-study-curcumin-reduces-liver-fat-inflammation.html
